AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX 11,526
+82 (0.72%)
Aug 14, 2025, 3:45 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $14.46B USD in the quarter ending June 30, 2025, with 11.74% growth. This brings the company's revenue in the last twelve months to $56.50B, up 15.00% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$56.50B
Revenue Growth
+15.00%
P/S Ratio
4.30
Revenue / Employee
$599.16K
Employees
94,300
Market Cap
177.46B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| Oxford Nanopore Technologies | 183.19M |
| HUTCHMED (China) | 439.54M |
| Genus | 671.60M |
AstraZeneca News
- 1 day ago - The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact - PRNewsWire
- 1 day ago - UK Government, Eli Lilly Partner To Target Obesity Health Gaps - Benzinga
- 2 days ago - AstraZeneca: Great Portfolio, But Not A Great Price - Seeking Alpha
- 4 days ago - Melrose boss soars to top of the Footsie pay league - This is Money
- 7 days ago - Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG) - Benzinga
- 8 days ago - SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook - Seeking Alpha
- 9 days ago - EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data - Benzinga
- 9 days ago - SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - PRNewsWire